Shopping Cart 0
Cart Subtotal
AED 0

Newron Pharmaceuticals SpA (NWRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Newron Pharmaceuticals SpA (Newron) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company's marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newron's other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co., Ltd. It operates along with its subsidiaries in the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.

Newron Pharmaceuticals SpA (NWRN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Newron Pharma Enters Into Co-Development Agreement With Zambon 11

Licensing Agreements 12

Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12

Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14

Equity Offering 16

Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16

Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17

Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18

Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19

Newron Pharma to Raise Funds through Public Offering of Shares 21

Newron Pharma Announces Private Placement Of Shares For USD 21 Million 22

Newron Pharma Completes Private Placement Of Shares For USD 4.8 Million 24

Acquisition 25

Newron Pharma Completes Acquisition Of NeuroNova For USD 12 Million 25

Newron Pharmaceuticals SpA-Key Competitors 27

Newron Pharmaceuticals SpA-Key Employees 28

Newron Pharmaceuticals SpA-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Sep 13, 2018: Newron reports half-year 2018 results 30

Mar 01, 2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018 32

Sep 14, 2017: Newron reports half-year 2017 results 35

Mar 02, 2017: Newron announces 2016 financial results and provides outlook for 2017 37

Corporate Communications 38

Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson's disease in Japan and Asia 38

Product News 39

10/25/2017: Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting 39

07/11/2017: XADAGO (Safinamide) Now Available in the U.S. for Parkinson's Disease Patients 40

05/12/2017: Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago (safinamide) 41

04/10/2017: Zambon Launches Xadago (Safinamide) In Portugal For Patients With Mid- To Late-Stage Parkinson's Disease 42

03/21/2017: FDA approves drug to treat Parkinson's disease 43

03/02/2017: Newron Provides Update on Sarizotan 44

03/02/2017: Newron Pharmaceuticals Provides Update on Xadago (safinamide) 45

02/08/2018: Newron Pharmaceuticals Announces Change in the Board of Directors 46

02/01/2018: Primary Endpoint Met In Phase II/III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan 47

Product Approvals 48

Jun 12, 2017: Zambon's Xadago Rejects For Use Within NHS Scotland 48

Clinical Trials 49

Jun 13, 2018: Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome 49

May 17, 2017: Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age 50

Other Significant Developments 51

Mar 27, 2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018 51

Dec 11, 2017: Newron Provides End of Year Corporate Update 52

Nov 07, 2017: Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Newron Pharmaceuticals SpA, Deals By Therapy Area, 2012 to YTD 2018 9

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Newron Pharma Enters Into Co-Development Agreement With Zambon 11

Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12

Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14

Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16

Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17

Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18

Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19

Newron Pharma to Raise Funds through Public Offering of Shares 21

Newron Pharma Announces Private Placement Of Shares For USD 21 Million 22

Newron Pharma Completes Private Placement Of Shares For USD 4.8 Million 24

Newron Pharma Completes Acquisition Of NeuroNova For USD 12 Million 25

Newron Pharmaceuticals SpA, Key Competitors 27

Newron Pharmaceuticals SpA, Key Employees 28

Newron Pharmaceuticals SpA, Subsidiaries 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Newron Pharmaceuticals SpA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Newron Pharmaceuticals SpA (Newron) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company's marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newron's other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co., Ltd. It operates along with its subsidiaries in the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.

Newron Pharmaceuticals SpA (NWRN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Newron Pharma Enters Into Co-Development Agreement With Zambon 11

Licensing Agreements 12

Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12

Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14

Equity Offering 16

Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16

Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17

Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18

Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19

Newron Pharma to Raise Funds through Public Offering of Shares 21

Newron Pharma Announces Private Placement Of Shares For USD 21 Million 22

Newron Pharma Completes Private Placement Of Shares For USD 4.8 Million 24

Acquisition 25

Newron Pharma Completes Acquisition Of NeuroNova For USD 12 Million 25

Newron Pharmaceuticals SpA-Key Competitors 27

Newron Pharmaceuticals SpA-Key Employees 28

Newron Pharmaceuticals SpA-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Sep 13, 2018: Newron reports half-year 2018 results 30

Mar 01, 2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018 32

Sep 14, 2017: Newron reports half-year 2017 results 35

Mar 02, 2017: Newron announces 2016 financial results and provides outlook for 2017 37

Corporate Communications 38

Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson's disease in Japan and Asia 38

Product News 39

10/25/2017: Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting 39

07/11/2017: XADAGO (Safinamide) Now Available in the U.S. for Parkinson's Disease Patients 40

05/12/2017: Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago (safinamide) 41

04/10/2017: Zambon Launches Xadago (Safinamide) In Portugal For Patients With Mid- To Late-Stage Parkinson's Disease 42

03/21/2017: FDA approves drug to treat Parkinson's disease 43

03/02/2017: Newron Provides Update on Sarizotan 44

03/02/2017: Newron Pharmaceuticals Provides Update on Xadago (safinamide) 45

02/08/2018: Newron Pharmaceuticals Announces Change in the Board of Directors 46

02/01/2018: Primary Endpoint Met In Phase II/III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan 47

Product Approvals 48

Jun 12, 2017: Zambon's Xadago Rejects For Use Within NHS Scotland 48

Clinical Trials 49

Jun 13, 2018: Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome 49

May 17, 2017: Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age 50

Other Significant Developments 51

Mar 27, 2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018 51

Dec 11, 2017: Newron Provides End of Year Corporate Update 52

Nov 07, 2017: Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Newron Pharmaceuticals SpA, Deals By Therapy Area, 2012 to YTD 2018 9

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Newron Pharma Enters Into Co-Development Agreement With Zambon 11

Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12

Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14

Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16

Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17

Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18

Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19

Newron Pharma to Raise Funds through Public Offering of Shares 21

Newron Pharma Announces Private Placement Of Shares For USD 21 Million 22

Newron Pharma Completes Private Placement Of Shares For USD 4.8 Million 24

Newron Pharma Completes Acquisition Of NeuroNova For USD 12 Million 25

Newron Pharmaceuticals SpA, Key Competitors 27

Newron Pharmaceuticals SpA, Key Employees 28

Newron Pharmaceuticals SpA, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Newron Pharmaceuticals SpA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.